About blinatumo mab
Bispecific CD19-directed CD3 T-cell engager antibody
Used for
- Treats B-cell precursor acute lymphoblastic leukemia (ALL), including some relapsed or persistent cases.
Usual adult dose
Continuous intravenous infusion: usually 9 micrograms daily initially, then 28 micrograms daily; schedules vary by treatment phase.
Usual dose in children
Continuous intravenous infusion: dose is based on body surface area, usually 5 micrograms/m² daily initially, then 15 micrograms/m² daily; schedules vary.
Common side effects
- Fever, headache, nausea, and fatigue
- Low blood-cell counts and infections
- Infusion reactions
- Nervous-system effects, including confusion or seizures
Important warnings
- Can cause severe cytokine release syndrome and life-threatening neurological effects.
- Treatment requires close monitoring, especially at initiation and after treatment interruptions.
- May cause serious infections, liver problems, or tumor lysis syndrome.
- Administered by continuous infusion; follow specialist instructions for pump and line care.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for at least 48 hours after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment and for at least 48 hours after the last dose.
Interactions
- Live vaccines should generally be avoided during treatment and until immune recovery.
- Other medicines affecting the immune system may increase infection or treatment-related risks.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.